Background: Patients with nonischemic cardiomyopathies (NICMs) are at a risk for end-stage heart failure and death from ventricular arrhythmias. Implanted defibrillators (ICDs) protect against sudden arrhythmic death, but several studies suggest that ventricular arrhythmias are associated with worse outcomes despite ICDs.
Objectives: This study evaluated the relationship of ventricular tachycardia (VT) with total mortality and nonsudden cardiovascular death (NSCVD) in NICM patients with ICDs enrolled in 2 multicentre trials.
Current genotoxicity testing strategies face several challenges, including a high incidence of misleading positive results that lead to unnecessary animal testing, limited mechanistic insights, insufficient integration of innovative methodologies, and a lack of quantitative assessment. Despite rapid advancements in technology and scientific understanding, genotoxicity testing batteries have remained largely unchanged for years. To modernize genotoxicity assessment and incorporate innovative approaches, the development of Integrated Approaches for Testing and Assessment (IATAs) is essential.
View Article and Find Full Text PDFBackground: The discovery of CRISPR/Cas9 and its subsequent accessibility in daily research initiated a new era in genome editing. This game-changing genetic instrument enabled a vast array of challenging applications requiring site-specific genome engineering as well as applications involving the equipment of cells with additional genetic traits. Despite the undisputed benefits of this technology, for facile and efficient selection of successfully manipulated cells selectable markers remain indispensable.
View Article and Find Full Text PDFCirc Arrhythm Electrophysiol
August 2025
Background: In patients with nonischemic cardiomyopathy and no late gadolinium enhancement (LGE) on cardiac magnetic resonance, risk prediction for the occurrence of sustained ventricular arrhythmias (VA) is challenging. Global and regional sympathetic denervation has been associated with VA in patients with ischemic cardiomyopathy. Its prognostic relevance in nonischemic cardiomyopathy is unknown.
View Article and Find Full Text PDFBackground: Systemic right ventricle (sRV) patients are at an increased risk of developing heart failure. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) could be a valuable treatment option. This study investigated the changes in ventricular function in sRV failure patients in the first year after starting SGLT2i.
View Article and Find Full Text PDF